This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Henry Schein, Inc. Presents at Stifel Jaws & Paws Conference, May-30-2024 10:20 AM
Transcript : Henry Schein, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 11:20 AM
Henry Schein Seeks Acquisitions CI
Transcript : Henry Schein, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM
Henry Schein Extends Special Olympics Sponsorship Through 2025 MT
UBS Adjusts Price Target on Henry Schein to $80 From $82, Maintains Neutral Rating MT
Barrington Ups Price Target on Henry Schein to $92 From $90, Maintains Outperform Rating MT
Goldman Sachs Adjusts Price Target on Henry Schein to $74 From $76 MT
Baird Adjusts Price Target on Henry Schein to $81 From $83, Maintains Neutral Rating MT
Tranche Update on Henry Schein, Inc.'s Equity Buyback Plan announced on December 13, 2018. CI
Transcript : Henry Schein, Inc., Q1 2024 Earnings Call, May 07, 2024
Stocks Mostly Up Pre-Bell Ahead of Latest Earnings Releases; Asia, Europe Rise MT
Henry Schein's Q1 Non-GAAP Earnings Decline, Revenue Rises MT
Earnings Flash (HSIC) HENRY SCHEIN Reports Q1 Revenue $3.17B, vs. Street Est of $3.20B MT
Earnings Flash (HSIC) HENRY SCHEIN Reports Q1 EPS $1.10, vs. Street Est of $1.01 MT
Henry Schein, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024 CI
Henry Schein, Inc. Revises Earnings Guidance for the Year 2024 CI
Leerink Partners Adjusts Henry Schein's Price Target to $77 From $82, Keeps Market Perform Rating MT
Constellation Brands, Inc: Cash machine Our Logo
Henry Schein, Inc. Announces Appointment of Members to the Company?S Executive Management Committee CI
Henry Schein Closes Acquisition of Majority Stake in TriMed MT
Henry Schein, Inc. completed the acquisition of an unknown majority interest in TriMed, Inc. CI
Viome Is Partnering with Henry Schein, Inc. to Provide Better Access to Oral Health Pro with Cancerdetect CI
Henry Schein Insider Sold Shares Worth $477,620, According to a Recent SEC Filing MT
JPMorgan Adjusts Henry Schein's Price Target to $88 From $82, Reiterates Overweight Rating MT
Chart Henry Schein, Inc.
More charts
Henry Schein, Inc. specializes in the distribution of care products and services intended for health professionals (doctors, surgeons, dentists, veterinary laboratories and clinics). Net sales break down by activity as follows: - distribution of health care products and equipment (93.5%): dental products and equipment (65.4% of net sales; consumable products, laboratory equipment, print materials, implants, anesthetics, etc.) and medical equipment (34.6%; medicines, vaccines, vitamins, surgical material, diagnostic tests, etc.); - other (6.5%): sale and integration of management software, financial, training, maintenance and equipment repair services. The United States account for 69.9% of net sales.Henry Schein, Inc. specializes in the distribution of care products and services intended for health professionals (doctors, surgeons, dentists, veterinary laboratories and clinics). Net sales break down by activity as follows: - distribution of health care products and equipment (93.5%): dental products and equipment (65.4% of net sales; consumable products, laboratory equipment, print materials, implants, anesthetics, etc.) and medical equipment (34.6%; medicines, vaccines, vitamins, surgical material, diagnostic tests, etc.); - other (6.5%): sale and integration of management software, financial, training, maintenance and equipment repair services. The United States account for 69.9% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
70.14 USD
Average target price
79.75 USD
Spread / Average Target
+13.70%
Consensus
  1. Stock Market
  2. Equities
  3. HSIC Stock
  4. News Henry Schein, Inc.
  5. Goldman Sachs Adjusts Price Target on Henry Schein to $74 From $76